The Netherlands Cancer Institute in Amsterdam was founded in 1913 by, among others, the surgeon Jacob Rotgans. The NKI, together with the Antoni van Leeuwenhoekziekenhuis, is formed into the NKI-AVL, which combines a scientific research institute with a specialized clinic focused on combating the disease cancer.

During the past decade, NKI-AVL conducted 157 clinical trials. In the 10-year time frame, 157 clinical trials started and 26 clinical trials were completed, i.e. on average, 16.6% percent of trials that started reached the finish line to date. In the past 5 years, 73 clinical trials started and 23 clinical trials were completed. i.e. 31.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "NKI-AVL" #1 sponsor was "The Netherlands Cancer Institute" with 65 trials, followed by "European Organisation for Research and Treatment of Cancer - EORTC" with 27 trials sponsored, "Hoffmann-La Roche" with 23 trials sponsored, "Radboud University Medical Center" with 10 trials sponsored and "Janssen Research & Development, LLC" with 10 trials sponsored. Other sponsors include 98 different institutions and companies that sponsored additional 64 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "NKI-AVL" #1 collaborator was "Merck Sharp & Dohme LLC" with 11 trials as a collaborator, "ZonMw: The Netherlands Organisation for Health Research and Development" with 9 trials as a collaborator, "Dutch Cancer Society" with 8 trials as a collaborator, "The Netherlands Cancer Institute" with 8 trials as a collaborator and "Bristol-Myers Squibb" with 6 trials as a collaborator. Other collaborators include 160 different institutions and companies that were collaborators in the rest 124 trials.

According to Clinical.Site data, the most researched conditions in "NKI-AVL" are "Breast Cancer" (23 trials), "Colorectal Cancer" (9 trials), "Melanoma" (9 trials), "Unspecified Adult Solid Tumor, Protocol Specific" (9 trials) and "Ovarian Cancer" (8 trials). Many other conditions were trialed in "NKI-AVL" in a lesser frequency.

Most popular intervention types in "NKI-AVL" are "Drug" (178 trials), "Radiation" (29 trials), "Procedure" (25 trials), "Biological" (23 trials) and "Other" (20 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (14 trials), "Pembrolizumab" (14 trials), "Placebo" (13 trials), "Nivolumab" (12 trials) and "Carboplatin" (7 trials). Other intervention names were less common.

The vast majority of trials in "NKI-AVL" are 193 trials for "All" genders, 25 trials for "Female" genders and 17 trials for "Male" genders.

Currently, there are NaN active trials in "NKI-AVL". 2 are not yet recruiting, 60 are recruiting, 43 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 87 completed trials in NKI-AVL, 2 suspended trials, and 18 terminated clinical trials to date.

Out of the total trials that were conducted in NKI-AVL, 58 "Phase 1" clinical trials were conducted, 89 "Phase 2" clinical trials and 73 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 22 trials that are defined as “Not Applicable".

NKI-AVL has several departments that took part in Clinical trials: "Antoni Van Leeuwenhoek Ziekenhuis; Inwendige Geneeskunde" - 3 trials, "NKI-AVL, Department of Thoracic-Oncology" - 3 trials, "Antoni Van Leeuwenhoek Ziekenhuis; Gastro-Enterologie" - 2 trials